Consort Medical (LON:CSRT)‘s stock had its “buy” rating reaffirmed by analysts at Shore Capital in a research report issued on Tuesday.
Several other equities analysts also recently commented on CSRT. Stifel Nicolaus restated a “buy” rating and issued a GBX 1,250 ($16.82) price target on shares of Consort Medical in a research note on Thursday, November 9th. N+1 Singer downgraded shares of Consort Medical to a “hold” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of GBX 1,188.17 ($15.99).
Shares of Consort Medical (LON:CSRT) traded up GBX 17 ($0.23) during midday trading on Tuesday, reaching GBX 1,166 ($15.69). The company’s stock had a trading volume of 3,327 shares, compared to its average volume of 22,318. Consort Medical has a 52 week low of GBX 960 ($12.92) and a 52 week high of GBX 1,180 ($15.88).
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
What are top analysts saying about Consort Medical plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Consort Medical plc and related companies.